Bausch Health Companies (TSE:BHC) Trading Down 2.3% – Time to Sell?

Bausch Health Companies Inc. (TSE:BHC) dropped 2.3% during mid-day trading on Friday . The stock traded as low as C$6.77 and last traded at C$6.78. Approximately 292,697 shares traded hands during mid-day trading, a decline of 39% from the average session volume of 477,546 shares. The stock had previously closed at C$6.94.

Bausch Health Companies Stock Performance

The company has a debt-to-equity ratio of -1,009.96, a current ratio of 1.32 and a quick ratio of 0.58. The company’s fifty day moving average price is C$7.12 and its 200 day moving average price is C$7.79. The company has a market cap of C$2.53 billion, a PE ratio of -2.09, a P/E/G ratio of 0.21 and a beta of 0.97.

Bausch Health Companies (TSE:BHC) last released its quarterly earnings results on Wednesday, April 29th. The company reported C$1.08 earnings per share for the quarter. The business had revenue of C$3.51 billion for the quarter. Bausch Health Companies had a negative net margin of 13.54% and a positive return on equity of 120.43%. On average, equities research analysts predict that Bausch Health Companies Inc. will post 5.5472637 earnings per share for the current year.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.